ISA Pharmaceuticals to present at the ASCO Annual Meeting 2024

16 Apr 2024

An abstract detailing results from a randomized, placebo-controlled trial in advanced head and neck cancer, was accepted for oral presentation

Results provide key insights for the clinical application of cancer vaccines

Oegstgeest, 16 April 2024 – ISA today announced acceptance of its ISA101b study abstract as an oral presentation at the upcoming 2024 American Society of Clinical Oncology (ASCO) Annual meeting. This abstract describes results of a randomized trial in advanced head and neck cancer with its lead therapeutic vaccine ISA101b.  These results provide key insights in the clinical application of cancer vaccines.

ISA101b is a cancer vaccine that targets human papillomavirus type

Read more »